Mesenchymal stromal cell (MSC) therapies combined with renal pulsed focused ultrasound (pFUS) pretreatment increase MSC homing and improve cisplatin-induced acute kidney injury (AKI) better than MSC alone. However, mechanisms underlying improved outcomes remain unknown. We hypothesize pFUS up-regulates renal interferon-γ (IFNγ) and stimulates MSC to produce interleukin-10 (IL-10) after migrating to kidneys. To demonstrate initially, MSC cultured with IFNγ up-regulated IL-10. More MSC-derived IL-10 was detected in kidneys when IFNγ-stimulated MSC were infused and they improved AKI better than unstimulated MSC. Next, IFNγ-knockout mice with AKI received pFUS+MSC, but MSC-derived IL-10 expression and AKI were similar to using MSC alone. AKI in wild-type mice receiving pFUS and IL-10-deficient MSC was also unimproved compared to administering IL-10-deficient MSC alone. Indoleamine 2,3-dioxygenase (IDO), an anti-inflammatory enzyme upregulated in MSC by IFNγ, was up-regulated during AKI, but was not further elevated in MSC from pFUS-treated kidneys, suggesting that IDO is not involved in improved AKI healing by pFUS+MSC. These data suggest IFNγ is up-regulated by pFUS and after i.v.-infused MSC home to pFUS-treated kidneys, IFNγ stimulates additional IL-10 production by MSC to improve AKI. Analogous mechanisms of ultrasound-treated tissue microenvironments stimulating therapeutic MSC may exist in other pathologies where adjuvant ultrasound techniques are successful.
system and stimulate endogenous regeneration of damaged tissues. 5 The non-engrafting immunomodulatory capacity of MSC has been shown effective in disease models where inflammation is critical to pathogenesis, including graft-versus-host disease, 6 ischaemic events, 7 and autoimmune diseases. 8 The clinical data regarding MSC therapies are mixed, 9 leading to wide-ranging efforts to alter MSC biodistribution following systemic infusion (primarily evade lung clearance 10 ) and improve their persistence, potency and function. The simplest modifications to improve efficacy include harvesting MSCs from different source tissues or altering routes of administration, cell doses and dosing schedules.
More sophisticated techniques attempt to improve trafficking and homing of systemically infused MSC. [11] [12] [13] [14] [15] Improved targeting of systemically infused MSC has been demonstrated by genetically and/or chemically modifying MSC, 11, 12, 15 or physically and/or chemically modifying local host tissue. 13, 14 For example, in vitro preconditioning by culturing with cytokines, growth factors or under hypoxia has improved MSC physiology, biodistribution and potency in vivo by up-regulating production of specific anti-inflammatory cytokines or trophic factors. 16 We have used pulsed focused ultrasound (pFUS) to increase homing of intravenous (i.v.)-injected MSC to desired locations and shown associations with improved pathology. [17] [18] [19] [20] [21] [22] Image-guided FUS is a noninvasive modality which is a clinically approved treatment for thermal ablation of patients with essential tremor, uterine fibroids and prostate cancer. [23] [24] [25] pFUS minimizes heating and allows acoustic mechanical effects to predominate. We have characterized the molecular biological effects of pFUS mechanotransduction in various tissues and show that pFUS stimulates local release of cytokines, chemokines, and trophic factors (CCTF) into the microenvironment and up-regulates cell adhesion molecules on endothelial cells. 17, 18 This local molecular biological response to pFUS represents chemoattractants that further increase homing of systemically infused MSC to sonicated muscle and kidneys.
In mouse models of cisplatin-induced acute kidney injury (AKI), i.v.-infused MSC have some intrinsic capability to home to kidneys and improve AKI. 26 We further improved this approach by administering pFUS to kidneys prior to human MSC infusions, which led to increased MSC homing and better-improved AKI compared to MSC infusions without pFUS pretreatment. 17 While outcomes were greatly improved, the mechanism behind the improved therapy was unknown. We initially attributed improved outcomes to increased numbers of MSC homing to pFUS-treated tissue. However, a disproportionally high expression of MSC-produced human interleukin-10 (IL-10) was present in pFUS-treated kidneys, suggesting that homing to pFUS-treated kidneys elicited different MSC physiology compared to homing to unsonicated kidneys.
This study investigated whether MSC-derived IL-10 was critical for improved AKI outcomes following renal pFUS and what stimulated its increased expression. IL-10 is an anti-inflammatory cytokine that has been demonstrated to directly improve both cisplatin-and ischaemia/reperfusion-induced AKI. 27 We previously observed that pFUS alone stimulated AKI kidneys to increase the production of interferon (IFN)γ. 17 The potential involvement of IFNγ was intriguing, as culturing MSCs with pro-inflammatory cytokines "primes" MSCs to produce more anti-inflammatory factors and become a more effective therapeutic cell factory. 28, 29 We initially performed a simple in vitro preconditioning study of MSC by culturing them with recombinant IFNγ. We then employed combinations of transgenic IFNγ-deficient mice and IL-10-deficient MSCs to selectively probe the molecular mechanisms behind pFUS improving MSC therapy for AKI in vivo. 
| MATERIALS AND METHODS

| Animals and AKI
| Pulsed focused ultrasound
Twenty-four hours after cisplatin injection (D1), pFUS was delivered under ultrasound imaging guidance using a VIFU 2000 and E-Cube 12 (Alpinion, Bothell, WA). Mice were anaesthetized with isoflurane (2.5% in 100% O 2 ) and kidneys were sonicated using the following parameters: 1 MHz ultrasound, 4 MPa peak negative pressure, 10 ms pulse length, 5 Hz pulse repetition frequency, and 100 pulses per site. Sonication points were spaced 2 mm apart and the number of points varied depending on the size of the kidney (most kidneys were entirely treated using 9-12 loci). pFUS treatment alone did not alter AKI outcomes ( Figure S3 ). Mice that were treated to measure MSC homing were given unilateral pFUS and the contralateral kidney was used as the untreated internal control. Mice in treatment groups to measure AKI outcomes were given kidney pFUS bilaterally.
Groups that were not treated with pFUS received sham exposures (transducer power = 0 W) and were considered controls. 
| MSC culture and infusions
| Renal function measurements
Renal function was measured using assay kits (Sigma Aldrich, St.
Louis, MO). Blood urea nitrogen (BUN) was measured in serum spectrophotometrically following degradation by urease. Serum creatinine (SCr) was measured fluorometrically following degradation by creatininase; this assay reports results similar to high-pressure liquid chromatography methods. (Abcam) were incubated for 1 hour at room temperature. Blots were imaged using a ChemiDoc MP system (Bio-Rad, Hercules, CA).
| Histological analyses
Tissue sections were deparaffinized in xylenes and rehydrated. Anti- 
| Statistical analyses
Data are presented as the mean ± standard deviation. Pairwise comparisons were made using Student's t tests and multiple comparisons were made using one-way analysis of variance using Prism (v6 Graphpad Inc. La Jolla, CA). All statistical tests were two-sided and P values <0.05 were considered significant.
| RESULTS
| Stimulating human MSC with murine IFNγ increases MSC IL-10 production in vitro, and improves AKI better than unstimulated MSC
Preconditioning human MSC by culturing with recombinant murine IFNγ (250 U/mL) for 24 hours significantly increased (P < 0.05) in vitro production of IL-10 ( Figure 1A , Figure S1 ). MSCs preconditioned with IFNγ (+IFNγ) or cultured under normal conditions (−IFNγ) were intravenously (i.v.) injected into wild-type (WT) mice with AKI (n = 6/group). One day later, mice were killed and kidneys immunostained for human mitochondria to detect MSC ( Figure 1B ).
IFNγ preconditioning did not statistically change the number of MSC homing to AKI kidneys. Other groups of mice given either type of MSC (n = 6) were killed 3 days post-infusion. Small but statistically significant (P < 0.05) improvements in BUN and SCr were observed in mice that received the +IFNγ MSC compared to −IFNγ MSC mice ( Figure 1C ) and there was also a trend for lower KIM-1 expression (P = 0.051) ( Figure 1D ) following +IFNγ MSC treatment.
Moreover, there are fewer TUNEL-positive cells (P < 0.05) (Figure 1E ). Figure 1F shows significantly more human (MSC-produced)
IL-10 was detected in AKI kidneys that received +IFNγ MSC com- None of these treatment groups altered expression of murine renal IL-10 ( Figure 1G ).
| Additional protection afforded by pFUS+MSC is absent in IFNγ knock-out mice
IFNγ-KO mice (n = 6/group) were given cisplatin and then divided into three groups; cisplatin alone (untreated control); MSC alone; and pFUS+MSC. Healthy IFNγ-KO mice served as normal controls and were administered saline intraperitoneally (i.p.). pFUS alone was demonstrated not to alter AKI progression or outcomes 17 and therefore those controls were omitted from this and subsequent experi- alone cohort ( Figure 3B) . Similarly, both cell treatment cohorts significantly reduced KIM-1 expression ( Figure 3C ) and TUNEL-positive cells ( Figure 3D ), but the cohorts receiving MSC si-IL10 alone or in combination with pFUS were not significantly different from each other (all P > 0.05). IL-10 was not detected in kidneys from cisplatin-treated C3H mice that received infusions of MSC si-IL10 or pFUS+MSC si-IL10 (P > 0.05) when compared to untreated AKI controls ( Figure 3E ). Murine IL-10 did not change between WT AKI mice that received either treatment or those that served as untreated controls ( Figure 3F ).
| IDO expression is stimulated in MSC by AKIassociated IFNγ, but further increasing IFNγ levels with pFUS does not yield similar increases in IDO
We also investigated the role IDO, an important immuno-regulator of human MSC that is also stimulated by IFNγ. 32 ELISAs measured homing of MSC and improved renal function in rats following mercuric chloride injury. 44 In that study, ultrasound interaction with 
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